An observational study in Invasive Fungal Infections, sponsored by Hospital Universitario Evangelico de Curitiba. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by Hospital Universitario Evangelico de Curitiba · Observational
Invasive fungal infections (IFIs) are complications that happen in the hospital, usually in patients hospitalized for long periods in intensive care units (ICU) after invasive procedures, and in specific populations, such as cancer patients. The aim of this study is to determine the direct and indirect hospital costs with different formulations of amphotericin B (deoxycholate, lipid complex and liposomal) in different public and private hospitals in the city of Curitiba, Paraná, Brazil.
BACKGROUND There are several American studies on the costs that the antifungal represents in the hospital bills, but in Brazil we do not have this type of study (WINGARD 2007; GREENE 2007). The American studies cannot be extrapolated to Brazil because the cost of drugs is different as well as other hospital charges. Furthermore, in Brazil spending on public medicine, governed by the Unified Health System (SUS) are different from those employed in the complementary health services (private health services). For these reasons, knowledge of the percentage they represent in the antifungal hospital bills in order to define the actual cost-effectiveness of different formulations of amphotericin B, considering length of hospital adverse events and mortality is needed.
OBJECTIVES:
Determine the direct and indirect hospital costs with different formulations of amphotericin B (deoxycholate, lipid complex and liposomal) in different public and private hospitals in the city of Curitiba, Paraná, Brazil.
Specifics
METHODS
This is a retrospective, observational, cohort study economic. Database of admissions of patients who used antifungal in all private hospital from an specific private health system (more than 5 hospitals) and databases of two large public hospitals in Curitiba (Evangelical University and the Clinical Hospital).
Patients over 18 years of age who used any formulation of amphotericin B will be included.
The data will be evaluated by the principal diagnosis ICD10 obtained at admission or discharge, the total length of stay, length of hospital stay before antifungal start, length of stay after initiation of antifungal drug, which formulation of amphotericin B used, the necessity and amount of dialysis. Also we will assess the final outcome of the patient (death or cure). Other epidemiological data such as age and gender will be evaluated.
A cost analysis will be based on total bill of the patient, the cost of antifungal, cost throughout the dialysis procedure, cost of laboratory tests used in monitoring during treatment with amphotericin (complete blood count, electrolytes, renal function, partial urine, function liver, electrocardiogram). The cost will be measured in American Dollar. These data were obtained from a similar study used for costing with antifungals in invasive aspergillosis in the USA (KIM 2011).
Data will be analyzed according to the type of variable. Means or medians will be used for continuous variables with standard deviation. Statistical methods for comparing means or medians will be parametric or non-parametric, as well as chi-square test for dichotomous variables. The data will be considered statistically significant when a difference of 5% (p \<0.05) occur. Other multivariable method can be applied according with the results.
Informed consent is not necessary because is a retrospective cohort with data obtained from medical charts, without any intervention.
Principal investigator and co-investigator will be the sponsor for fill the request. All the survey will be fulfilled by investigator and co-investigator. The survey is attached in the end of the project.
This study will be sent for ethics committee for approval before start.
152 studies on the registry are indexed under Invasive Fungal Infections; 35 are open to participants now.
This study's planned enrollment of 200 is above the median of 125 across 72 observational studies indexed under Invasive Fungal Infections.
Browse Invasive Fungal Infections studies →Hospital Universitario Evangelico de Curitiba is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a study of pharmacoeconomics. Patients who used amphotericin B e total cost of hospitalization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Amphotericin B desoxicholate
Other: None intervention
Amphotericin B complex lipid
Amphotericin B liposomal
Cost
The outcome will measured in US dollar.
Time frame: Fungal infection at day 100
No study locations are listed for this record.
This study is status unknown, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario Evangelico de Curitiba